diclofenac has been researched along with Cholera Infantum in 81 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)." | 9.13 | Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008) |
| " To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)." | 9.12 | Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007) |
| "To compare the efficacy and safety of aceclofenac (AC) and tenoxicam (TX) in the treatment of rheumatoid arthritis (RA), a multicentric parallel, randomized, double-blind trial of three months duration was performed in 292 patients: 145 were randomized to the AC treatment group and 147 to the TX treatment group." | 9.08 | Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. ( Alonso-Ruiz, A; Ansoleaga, JJ; Perez-Ruiz, F, 1996) |
| "To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis." | 9.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 9.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 9.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 9.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Eighty patients with osteoarthritis were randomly assigned to either piroxicam (20 mg daily) or diclofenac (75-150 mg daily) in a 12-week double-blind, parallel groups study." | 9.06 | A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis. ( Buchanan, WW; Gerecz-Simon, E; Kean, WF; Rooney, PJ; Soper, WY; Tugwell, P, 1990) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 6.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Patients ≥50 years with osteoarthritis or rheumatoid arthritis were randomized to etoricoxib or diclofenac in a prespecified intent-to-treat analysis of three double-blind randomized trials." | 5.14 | Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2010) |
| "A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)." | 5.13 | Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008) |
| " To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)." | 5.12 | Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007) |
| " In the first few weeks of treatment, the mean changes in some variables (VAS, which assessed walking pain, standing pain and stiffness, as well as Lequesne's functional index) of the DJW group were significantly lower than those of the diclofenac group." | 5.11 | Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. ( Kunanusorn, P; Lhieochaiphunt, S; Pojchamarnwiputh, S; Pruksakorn, S; Rojanasthien, N; Sananpanich, K; Teekachunhatean, S, 2004) |
| "To compare the efficacy and safety of aceclofenac (AC) and tenoxicam (TX) in the treatment of rheumatoid arthritis (RA), a multicentric parallel, randomized, double-blind trial of three months duration was performed in 292 patients: 145 were randomized to the AC treatment group and 147 to the TX treatment group." | 5.08 | Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. ( Alonso-Ruiz, A; Ansoleaga, JJ; Perez-Ruiz, F, 1996) |
| "To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis." | 5.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 5.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "Eighty patients with osteoarthritis were randomly assigned to either piroxicam (20 mg daily) or diclofenac (75-150 mg daily) in a 12-week double-blind, parallel groups study." | 5.06 | A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis. ( Buchanan, WW; Gerecz-Simon, E; Kean, WF; Rooney, PJ; Soper, WY; Tugwell, P, 1990) |
| "6 g/day, in 194 patients with rheumatoid arthritis (RA) in Study 1 and with those of naproxen, 1000 mg/day, in 223 patients with RA in Study 2." | 5.06 | Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. ( Kolodny, AL, 1988) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 5.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "Topical NSAIDs, followed by oral NSAIDs and acetaminophen with or without diclofenac, showed the most convincing and attractive benefit-harm ratio for patients with acute pain from non-low back, musculoskeletal injuries." | 5.05 | Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries : A Systematic Review and Network Meta-analysis of Randomized Trials. ( Agarwal, A; Akbari-Kelachayeh, K; Ali, SH; Brar, S; Busse, JW; Chang, Y; Chen, E; Couban, R; Craigie, S; Culig, K; Das, A; Emary, P; Florez, ID; Goshua, A; Guyatt, GH; Hong, PJ; Lok, A; May, C; Morgan, RL; Noor, ST; Oparin, Y; Pozdnyakov, A; Ross, SA; Sadeghirad, B; Shergill, Y; Sivananthan, L; Yao, W; Zihayat, B, 2020) |
| " An increased risk of acute myocardial infarction and heart failure is observed with all NSAIDs, while an elevated risk of hemorrhagic stroke appears to be restricted to the use of diclofenac and meloxicam." | 5.01 | Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? ( Al-Daghri, N; Bruyère, O; Chapurlat, R; Cooper, C; Herrero-Beaumont, G; Rannou, F; Reginster, JY; Roth, R; Uebelhart, D, 2019) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " In a cohort study comparing the risk of upper gastrointestinal complications in celecoxib or traditional NSAIDs (diclofenac, ibuprofen) initiators with rheumatoid arthritis and osteoarthritis, we (1) aggregated medications and International Classification of Diseases-9 (ICD-9) diagnoses into hierarchies of the Anatomical Therapeutic Chemical classification (ATC) and the Clinical Classification Software (CCS), respectively, and (2) sampled the full cohort using techniques validated by simulations to create 9,600 samples to compare 16 aggregation scenarios across 50% and 20% samples with varying outcome incidence and exposure prevalence." | 3.79 | Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. ( Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T, 2013) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine." | 3.70 | [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| "The incidence of gastrointestinal disorders was 5." | 2.74 | Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. ( Altman, RD; Barthel, HR; Gold, MS; Haselwood, D; Longley, S, 2009) |
| " The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0." | 2.74 | Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). ( Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C, 2009) |
| ": Sixty-five healthy male subjects were randomized to receive 8 days' dosing with lumiracoxib 200 mg twice daily (b." | 2.71 | Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. ( Branson, J; Ford, M; Kellett, N; Mair, S; Milosavljev, S; Rordorf, C; Scott, G, 2003) |
| "Diclofenac-treated patients experienced statistically significant elevations in mean hepatic transaminases and serum creatinine and reductions in haemoglobin concentration when compared to placebo, events not observed with celecoxib." | 2.70 | Celecoxib versus diclofenac in the management of osteoarthritis of the knee. ( Borenstein, D; Geis, GS; Lefkowith, JB; McKenna, F; Wallemark, C; Wendt, H, 2001) |
| " In previous studies, meloxicam has been found to be safe and effective in the treatment of osteoarthritis (OA) at doses of 7." | 2.69 | Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. ( Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 2.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " Gastric tolerance was assessed by endoscopy, which was performed at base-line, after the 14 day dosing period and after a 14 day follow-up period without treatment." | 2.66 | Comparison of the gastroduodenal tolerance of tenoxicam and diclofenac Na. A double-blind, endoscopically controlled study in healthy volunteers. ( Dammann, HG; Leucht, U; Müller, P; Simon, B, 1989) |
| "Ankylosing spondylitis is a systemic rheumatic disorder characterized by inflammation of the spine, sacroiliac, and large peripheral joints." | 2.66 | Efficacy of diclofenac in ankylosing spondylitis. ( Calabro, JJ, 1986) |
| " Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries." | 2.66 | Worldwide safety experience with diclofenac. ( Catalano, MA, 1986) |
| "To our knowledge, this is the first study to quantify and aggregate the continuous relationship between the risk of GI or CV events and the dosage of an NSAID." | 2.50 | Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. ( Miles, L; Mladsi, DM; Odom, DM; Ronquest, N; Saag, KG; Sherif, BN; Wang, J, 2014) |
| "We have previously reported that mice lacking the efflux transporter Mrp3 had significant intestinal injury after toxic diclofenac (DCF) challenge, and proposed that diclofenac acyl glucuronide (DCF-AG), as a substrate of Mrp3, played a part in mediating injury." | 1.43 | Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity. ( Manautou, JE; Scialis, RJ, 2016) |
| " The reference dose of Diclofenac used in all randomized controlled trials is 150 mg/die; this controlled release dosage allows to decrease the number of daily administrations, ensuring a better patient compliance, especially if elderly and/or in polytherapy." | 1.40 | [Diclofenac: update on tolerableness and spinal anti-inflammatory action]. ( Sandri, A, 2014) |
| " Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk." | 1.39 | Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. ( Simon, LS, 2013) |
| "Already considered a drug that can reverse the toxic side effects of NSAIDs, BPC 157 (10 μg/kg, 10 ng/kg) was strongly effective throughout the entire experiment when given (i) intraperitoneally immediately after diclofenac or (ii) per-orally in drinking water (0." | 1.37 | Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. ( Blagaic, AB; Brcic, L; Coric, M; Djakovic, Z; Djuzel, V; Drmic, D; Dzidic, S; Filipovic, M; Franjic, S; Gjurasin, M; Ilic, S; Klicek, R; Kolenc, D; Radic, B; Romic, Z; Seiwerth, S; Sever, M; Sikiric, P; Stambolija, V; Stupnisek, M; Zarkovic, K; Zoricic, I, 2011) |
| " Etoricoxib is partly metabolised by the cytochrome P450 isoenzyme CYP 3A4 and increases the bioavailability of ethinylestradiol." | 1.34 | Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. ( , 2007) |
| " However, user ability to discover the most common side effect to the drug seemed not to be affected." | 1.32 | Awareness and frequency of potential side effects on nonsteroidal anti-inflammatory drugs among the Jordanian patient population. ( Abdel-Hafiz, SM; Al-Safi, SA; Albsoul-Younes, AM; Jabateh, SK, 2004) |
| " This is due to the lower incidence of gastrointestinal adverse events with nimesulide, and the absence of serious gastrointestinal complications leading to hospitalization, which more than offset the higher acquisition cost of nimesulide." | 1.30 | Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece. ( Liaropoulos, L, 1999) |
| "The costs of treating gastroduodenal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are shown to increase the total cost of NSAID treatment to the Assurance-Maladie, the French national health insurance system." | 1.28 | The economic consequences of NSAID-induced gastropathy: the French context. ( de Pouvourville, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (14.81) | 18.7374 |
| 1990's | 21 (25.93) | 18.2507 |
| 2000's | 30 (37.04) | 29.6817 |
| 2010's | 15 (18.52) | 24.3611 |
| 2020's | 3 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Khanna, IK | 1 |
| Weier, RM | 1 |
| Yu, Y | 1 |
| Xu, XD | 1 |
| Koszyk, FJ | 1 |
| Collins, PW | 1 |
| Koboldt, CM | 1 |
| Veenhuizen, AW | 1 |
| Perkins, WE | 1 |
| Casler, JJ | 1 |
| Masferrer, JL | 1 |
| Zhang, YY | 1 |
| Gregory, SA | 1 |
| Seibert, K | 1 |
| Isakson, PC | 1 |
| Imai, T | 1 |
| Hazama, K | 1 |
| Kosuge, Y | 1 |
| Suzuki, S | 1 |
| Ootsuka, S | 1 |
| Sánchez, AB | 1 |
| Clares, B | 1 |
| Rodríguez-Lagunas, MJ | 1 |
| Fábrega, MJ | 1 |
| Calpena, AC | 1 |
| Busse, JW | 1 |
| Sadeghirad, B | 1 |
| Oparin, Y | 1 |
| Chen, E | 1 |
| Goshua, A | 1 |
| May, C | 1 |
| Hong, PJ | 1 |
| Agarwal, A | 1 |
| Chang, Y | 1 |
| Ross, SA | 1 |
| Emary, P | 1 |
| Florez, ID | 1 |
| Noor, ST | 1 |
| Yao, W | 1 |
| Lok, A | 1 |
| Ali, SH | 1 |
| Craigie, S | 1 |
| Couban, R | 1 |
| Morgan, RL | 1 |
| Culig, K | 1 |
| Brar, S | 1 |
| Akbari-Kelachayeh, K | 1 |
| Pozdnyakov, A | 1 |
| Shergill, Y | 1 |
| Sivananthan, L | 1 |
| Zihayat, B | 1 |
| Das, A | 1 |
| Guyatt, GH | 1 |
| Lai, EC | 1 |
| Shin, JY | 1 |
| Kubota, K | 1 |
| Man, KKC | 1 |
| Park, BJ | 1 |
| Pratt, N | 1 |
| Roughead, EE | 1 |
| Wong, ICK | 1 |
| Kao Yang, YH | 1 |
| Setoguchi, S | 1 |
| Shin, S | 1 |
| Jeong, HM | 1 |
| Chung, SE | 1 |
| Kim, TH | 1 |
| Thapa, SK | 1 |
| Lee, DY | 1 |
| Song, CH | 1 |
| Lim, JY | 1 |
| Cho, SM | 1 |
| Nam, KY | 1 |
| Kang, WH | 1 |
| Choi, YW | 1 |
| Shin, BS | 1 |
| Cooper, C | 1 |
| Chapurlat, R | 1 |
| Al-Daghri, N | 1 |
| Herrero-Beaumont, G | 1 |
| Bruyère, O | 1 |
| Rannou, F | 1 |
| Roth, R | 1 |
| Uebelhart, D | 1 |
| Reginster, JY | 2 |
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 1 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 2 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 4 |
| Lanas, A | 1 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 1 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 2 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Le, HV | 1 |
| Poole, C | 1 |
| Brookhart, MA | 2 |
| Schoenbach, VJ | 1 |
| Beach, KJ | 1 |
| Layton, JB | 1 |
| Stürmer, T | 1 |
| Simon, LS | 2 |
| Odom, DM | 1 |
| Mladsi, DM | 1 |
| Saag, KG | 1 |
| Sherif, BN | 1 |
| Miles, L | 1 |
| Ronquest, N | 1 |
| Wang, J | 1 |
| Sandri, A | 1 |
| Scialis, RJ | 1 |
| Manautou, JE | 1 |
| Combe, B | 1 |
| Swergold, G | 1 |
| McLay, J | 1 |
| McCarthy, T | 1 |
| Zerbini, C | 1 |
| Emery, P | 1 |
| Connors, L | 1 |
| Kaur, A | 5 |
| Curtis, S | 2 |
| Cannon, CP | 3 |
| Barthel, HR | 1 |
| Haselwood, D | 1 |
| Longley, S | 1 |
| Gold, MS | 1 |
| Altman, RD | 1 |
| Jiang, M | 1 |
| Zhao, J | 1 |
| Lu, A | 1 |
| Zha, Q | 1 |
| He, Y | 1 |
| Inotai, A | 1 |
| Rojkovich, B | 2 |
| Mészáros, A | 1 |
| Alekseeva, LI | 1 |
| Curtis, SP | 3 |
| Cryer, B | 2 |
| Ilic, S | 1 |
| Drmic, D | 1 |
| Franjic, S | 1 |
| Kolenc, D | 1 |
| Coric, M | 1 |
| Brcic, L | 1 |
| Klicek, R | 1 |
| Radic, B | 1 |
| Sever, M | 1 |
| Djuzel, V | 1 |
| Filipovic, M | 1 |
| Djakovic, Z | 1 |
| Stambolija, V | 1 |
| Blagaic, AB | 1 |
| Zoricic, I | 1 |
| Gjurasin, M | 1 |
| Stupnisek, M | 1 |
| Romic, Z | 1 |
| Zarkovic, K | 1 |
| Dzidic, S | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Wright, JM | 1 |
| Rordorf, C | 1 |
| Kellett, N | 1 |
| Mair, S | 1 |
| Ford, M | 1 |
| Milosavljev, S | 1 |
| Branson, J | 1 |
| Scott, G | 1 |
| Sell, S | 2 |
| Phillips, O | 1 |
| Handel, M | 1 |
| Amir, M | 1 |
| Shikha, K | 1 |
| Singh, G | 1 |
| Lanes, S | 1 |
| Triadafilopoulos, G | 1 |
| Albsoul-Younes, AM | 1 |
| Jabateh, SK | 1 |
| Abdel-Hafiz, SM | 1 |
| Al-Safi, SA | 1 |
| Mysler, E | 1 |
| Teekachunhatean, S | 1 |
| Kunanusorn, P | 1 |
| Rojanasthien, N | 1 |
| Sananpanich, K | 1 |
| Pojchamarnwiputh, S | 1 |
| Lhieochaiphunt, S | 1 |
| Pruksakorn, S | 1 |
| Rosenberg, JA | 1 |
| Goldstein, JL | 2 |
| Hawkey, CJ | 2 |
| Gitton, X | 1 |
| Hoexter, G | 1 |
| Richard, D | 2 |
| Weinstein, WM | 2 |
| Zeidler, H | 1 |
| May, M | 2 |
| Uberall, MA | 1 |
| Vergin, H | 1 |
| Schneeweiss, S | 1 |
| Solomon, DH | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Baraf, HS | 1 |
| Fuentealba, C | 1 |
| Greenwald, M | 1 |
| Brzezicki, J | 1 |
| O'Brien, K | 1 |
| Soffer, B | 1 |
| Polis, A | 1 |
| Bird, S | 1 |
| Einecke, D | 1 |
| Sieper, J | 1 |
| Klopsch, T | 1 |
| Richter, M | 1 |
| Kapelle, A | 1 |
| Rudwaleit, M | 1 |
| Schwank, S | 1 |
| Regourd, E | 1 |
| Singh, H | 1 |
| Krueger, K | 1 |
| Lino, L | 1 |
| Dore, R | 1 |
| Radominski, S | 1 |
| Zhang, Y | 1 |
| Simpson, R | 1 |
| Stricker, K | 1 |
| Murphy, V | 1 |
| Krammer, G | 1 |
| Rebuli, R | 1 |
| Fleischmann, R | 2 |
| Tannenbaum, H | 1 |
| Patel, NP | 1 |
| Notter, M | 1 |
| Sallstig, P | 1 |
| Guobis, G | 1 |
| Iushenaite, Ia | 1 |
| Geis, GS | 6 |
| Melarange, R | 2 |
| Blower, P | 1 |
| Spangler, R | 1 |
| Conforti, A | 1 |
| Donini, M | 1 |
| Brocco, G | 1 |
| Del Soldato, P | 1 |
| Benoni, G | 1 |
| Cuzzolin, L | 1 |
| Tammara, VK | 1 |
| Narurkar, MM | 1 |
| Crider, AM | 1 |
| Khan, MA | 1 |
| Melo Gomes, JA | 1 |
| Roth, SH | 2 |
| Zeeh, J | 1 |
| Bruyn, GA | 1 |
| Woods, EM | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 1 |
| DeLapp, RE | 1 |
| Jensen, CP | 1 |
| Perez-Ruiz, F | 1 |
| Alonso-Ruiz, A | 1 |
| Ansoleaga, JJ | 1 |
| Jockheck, M | 1 |
| Willms, R | 1 |
| Volkmann, R | 1 |
| Weller, S | 1 |
| Küsswetter, W | 1 |
| Kahan, A | 1 |
| Steinbrück, K | 1 |
| Alegre, C | 1 |
| Baumelou, E | 1 |
| Bégaud, B | 1 |
| Dequeker, J | 1 |
| Isomäki, H | 1 |
| Littlejohn, G | 1 |
| Mau, J | 1 |
| Papazoglou, S | 1 |
| Liaropoulos, L | 1 |
| Becvár, R | 1 |
| Urbanová, Z | 1 |
| Vlasáková, V | 1 |
| Vítová, J | 1 |
| Rybár, I | 1 |
| Maldyk, H | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Bernacka, K | 1 |
| Mackiewicz, S | 1 |
| Gömör, B | 1 |
| Siro, B | 1 |
| Bereczki, J | 1 |
| Toth, K | 1 |
| Sukenik, S | 1 |
| Green, L | 1 |
| Ehrenfeld, M | 1 |
| Pavelka, K | 1 |
| Llop, C | 1 |
| Paredes, S | 1 |
| Llor, C | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Pincus, T | 1 |
| Whelton, A | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Agrawal, NM | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Zhao, WW | 1 |
| Kent, JD | 1 |
| Lefkowith, JB | 2 |
| Verburg, KM | 1 |
| Yocum, D | 1 |
| Dalgin, P | 1 |
| Caldwell, J | 1 |
| Hall, D | 1 |
| Roszko, P | 1 |
| Soto Alvarez, J | 1 |
| McKenna, F | 1 |
| Borenstein, D | 1 |
| Wendt, H | 1 |
| Wallemark, C | 1 |
| Rahme, E | 1 |
| Joseph, L | 1 |
| Kong, SX | 1 |
| Watson, DJ | 2 |
| Pellissier, JM | 1 |
| LeLorier, J | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Ciucci, AG | 1 |
| Ciccolunghi, SN | 1 |
| Schubiger, BI | 1 |
| Reddrop, R | 1 |
| de Melo Gomes, JA | 1 |
| de Pouvourville, G | 1 |
| Bach, GL | 1 |
| Knill-Jones, RP | 1 |
| Bolten, W | 1 |
| Gomes, JA | 1 |
| Stead, H | 2 |
| Yanagawa, A | 1 |
| Fukumura, T | 1 |
| Matsui, H | 1 |
| Uemura, H | 1 |
| Endo, T | 1 |
| Nakagawa, T | 1 |
| Mizushima, Y | 1 |
| Wallemark, CB | 1 |
| Nicholson, PA | 1 |
| Gentry, C | 1 |
| O'Connell, C | 1 |
| Blower, PR | 1 |
| Gerecz-Simon, E | 1 |
| Soper, WY | 1 |
| Kean, WF | 1 |
| Rooney, PJ | 1 |
| Buchanan, WW | 1 |
| Müller, P | 1 |
| Dammann, HG | 1 |
| Leucht, U | 1 |
| Simon, B | 1 |
| Schlegel, SI | 1 |
| Paulus, HE | 1 |
| Kolodny, AL | 1 |
| Rimbau, V | 1 |
| Fernandez, MF | 1 |
| Guirao, I | 1 |
| Torralba, A | 1 |
| Izquierdo, E | 1 |
| Altman, R | 1 |
| Calabro, JJ | 1 |
| Catalano, MA | 1 |
| O'brien, WM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| The Effect of Chronic Pain Relief Over Knee Joint Area by Gua Sha Therapy[NCT03821194] | 40 participants (Anticipated) | Interventional | 2019-01-25 | Recruiting | |||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| The Effect of St. John's Wort Oil on Pain Intensity and Physical Functions in People With Knee Osteoarthritis: a Qualitative and Randomized Placebo-controlled Trial[NCT05663996] | 60 participants (Actual) | Interventional | 2017-12-25 | Completed | |||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301] | Phase 3 | 3,036 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
12 reviews available for diclofenac and Cholera Infantum
| Article | Year |
|---|---|
Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries : A Systematic Review and Network Meta-analysis of Randomized Trials.
Topics: Acetaminophen; Acute Pain; Administration, Oral; Administration, Topical; Analgesics, Opioid; Anti-I | 2020 |
Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Gastrointestinal Diseases; Humans; | 2019 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Dose-Response Relation | 2014 |
[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study pro
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Etoricoxib; Gastrointest | 2010 |
The double-edged sword of COX-2 selective NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibit | 2002 |
Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
Topics: Acute Disease; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibi | 2004 |
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Disea | 2006 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost of Illness; Diclofenac; Drug Combinations; Gastrointes | 1992 |
Non-steroidal and analgesic therapy in the elderly.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents; Apazone; Aspirin; Cen | 1986 |
34 trials available for diclofenac and Cholera Infantum
| Article | Year |
|---|---|
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergenci | 2009 |
Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Arthralgia; Diclofenac; Female; Gastrointes | 2009 |
Does gastrointestinal adverse drug reaction influence therapeutic effect in the treatment of rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Drug Therapy, Combination; Drugs, Chinese H | 2010 |
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase 2 | 2010 |
Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
Topics: Adolescent; Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofe | 2003 |
No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Diclofenac; Dose-Resp | 2004 |
Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Diclofenac; | 2004 |
Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dizziness; Double-Blind Method; Drugs, C | 2004 |
Safety and efficacy of lumiracoxib compared with NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; D | 2005 |
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofe | 2007 |
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito | 2008 |
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiova | 2008 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury | 2008 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
Efficacy and upper GI safety of diclofenac/misoprostol, piroxicam and naproxen in patients with osteoarthritis.
Topics: Diclofenac; Double-Blind Method; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Male; | 1993 |
Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Diclofenac; Double-Blind Method; Drug Combinations; Drug Therapy, Co | 1993 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1996 |
Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthr | 1998 |
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind M | 1998 |
Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dicl | 1999 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Topics: Adult; Aged; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Di | 2000 |
Celecoxib versus diclofenac in the management of osteoarthritis of the knee.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotra | 2001 |
The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diclofenac; Digestive S | 1992 |
The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis.
Topics: Adult; Aged; Diclofenac; Double-Blind Method; Drug Combinations; Duodenum; Female; Gastrointestinal | 1992 |
Possible mechanisms of gastroduodenal mucosal damage in volunteers treated with nonsteroidal antiinflammatory drugs--the usefulness of prodrugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Digestive System; Dinoprostone; Double-B | 1992 |
A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis.
Topics: Activities of Daily Living; Diclofenac; Double-Blind Method; Gastrointestinal Diseases; Humans; Midd | 1990 |
Comparison of the gastroduodenal tolerance of tenoxicam and diclofenac Na. A double-blind, endoscopically controlled study in healthy volunteers.
Topics: Adolescent; Adult; Diclofenac; Double-Blind Method; Duodenum; Gastrointestinal Diseases; Gastroscopy | 1989 |
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1988 |
International experiences with diclofenac in osteoarthritis.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; Diflunisal; Double-Blind Method; Gastrointestinal Dis | 1986 |
Efficacy of diclofenac in ankylosing spondylitis.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Gastrointestinal Dis | 1986 |
Worldwide safety experience with diclofenac.
Topics: Adult; Aged; Aspirin; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Diclo | 1986 |
36 other studies available for diclofenac and Cholera Infantum
| Article | Year |
|---|---|
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena | 1997 |
Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER.
Topics: Adverse Drug Reaction Reporting Systems; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Databases | 2022 |
Study of Melatonin as Preventive Agent of Gastrointestinal Damage Induced by Sodium Diclofenac.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Diclofenac | 2020 |
Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: A multi-database, international cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Databases, F | 2018 |
Simultaneous analysis of acetylcarnitine, proline, hydroxyproline, citrulline, and arginine as potential plasma biomarkers to evaluate NSAIDs-induced gastric injury by liquid chromatography-tandem mass spectrometry.
Topics: Acetylcarnitine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Biomarkers; Chromatogra | 2019 |
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclo | 2013 |
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2013 |
[Topical therapy of arthritis with diclofenac is safe].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Evidence-Based Medicine; Gastrointestinal Disea | 2014 |
[Diclofenac: update on tolerableness and spinal anti-inflammatory action].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood-Brain Barrier; Car | 2014 |
Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2 | 2016 |
[The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary--a cross sectional non interventional study].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cross-Sectional Studies; Cyclooxygen | 2010 |
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Behavior, | 2011 |
Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino) phenyl]acetic acid derivatives.
Topics: Acetates; Analgesics; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofena | 2004 |
Awareness and frequency of potential side effects on nonsteroidal anti-inflammatory drugs among the Jordanian patient population.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Awareness; Diclofenac; Drug Utilization; | 2004 |
NICE risk factors for gastrointestinal adverse events in diclofenac users in general practice in Germany: comment on the article of Thompson et al.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Fam | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; | 2007 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical | 2007 |
Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Carrageen | 1994 |
Acute anti-inflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Diclofenac; Edema; Female; Gastrointe | 1993 |
Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Chemical Phenomena; Chemistry, Pharmaceutica | 1994 |
Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhi | 1999 |
Criteria for selecting and using non-steroidal anti-inflammatory drugs in primary health care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Decision Making; Diclofenac; Drug Admini | 2000 |
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal | 2000 |
Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Dru | 2001 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
A review of spontaneously reported adverse drug reactions with diclofenac sodium (Voltarol).
Topics: Adult; Aged; Anticoagulants; Arthritis, Rheumatoid; Blood Cell Count; Central Nervous System; Diclof | 1979 |
Comparisons of tolerability findings in international clinical trials.
Topics: Arthritis, Rheumatoid; Aspirin; Cardiovascular System; Clinical Trials as Topic; Diclofenac; Drug To | 1979 |
The economic consequences of NSAID-induced gastropathy: the French context.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost of Illness; Diclofenac; Duodenal Ulce | 1992 |
Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Gastr | 1992 |
Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Dicl | 1991 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |
Comparative study of the gastrointestinal tolerance of diclofenac and aceclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gastrointestinal Diseases; Gastrointes | 1988 |
Adverse reactions to nonsteroidal anti-inflammatory drugs. Diclofenac compared with other nonsteroidal anti-inflammatory drugs.
Topics: Aged; Anaphylaxis; Anemia, Aplastic; Anti-Inflammatory Agents; Asthma; Blood Platelets; Chemical and | 1986 |
Special studies of diclofenac and safety: gastrointestinal, renal, hepatic, and other consequences of therapy.
Topics: Age Factors; Diclofenac; Endoscopy; Gastrointestinal Diseases; Humans; Kidney Diseases; Kinetics; Li | 1985 |